͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | Do you have a therapeutic asset in the childhood cancer space? C-Further wants to hear from you.
Our childhood cancer therapeutics consortium, C-Further, offers a supportive pathway to advance novel therapeutic assets. If selected, you’ll gain access to cutting-edge facilities, funding, resources and expertise to develop your discovery into a therapeutic for children and young people affected by cancer.
The next expression of interest deadline is 1 September 2025. |
| |
|
|
|
|
|
| Research careers – bridging the gap between postdoc and group leader |
| For many early-career researchers, taking that step from postdoc to independent group leader can feel daunting. To help address this, we created the Bridge to Academic Leadership programme, designed to help postdocs feel more confident and prepared for academic leadership.
We caught up with our Research Careers Programme Manager, Ally Walters, after concluding the journey with our first ever cohort from the programme. She takes us through the feedback from postdocs that helped shape the programme and shares the key lessons we hope they walked away with. |
| |
|
|
|
|
|
| | AI is already revolutionising cancer care, enabling advances in early detection, personalised treatment, drug discovery and beyond. However, the revolution is only possible with high-quality patient-derived data.
Joe Day leads data licensing at our innovation arm, Cancer Research Horizons. Joe spoke to Technology Networks about how his team aims to maximise the impact of cancer research data using AI.
The conversation touches on ethics, what it takes to build patient trust and what researchers can do to steer the AI revolution towards better outcomes for patients. | |
| | | | Cancer Research Horizons’ first Clinical Advisory Board brings together world-leading oncologists with expertise in early-phase clinical trials.
The board is chaired by Ruth Plummer (Newcastle University), who leads trials across all phases of drug development. She’s joined by Elena Garralda (Vall d’Hebron Institute of Oncology), a specialist in proof-of-concept trials for targeted therapies, Lillian Su (University of Toronto), an expert in cancer genomics, liquid biopsies and novel anti-cancer agents and Tim Yap (MD Anderson Cancer Center) who brings extensive experience in first-in-human trials and combination studies.
Together, the board will help guide and accelerate the development of novel cancer therapeutics emerging from their drug discovery division, Therapeutic Innovation. | |
|
---|
|
|
|
|
| | Last week, we had a fantastic three days in London for the Cancer Prevention Research Conference – many thanks to everyone who joined us for making it a truly inspiring meeting.
As we reflect on the insights from a packed programme of scientific talks, Q&A and networking, we’re pleased to announce that our co-host, the American Cancer Society, will be hosting next year’s event in Atlanta, USA, from 3–5 June 2026.
Save the date: 3-5 June 2026 Location: Atlanta, USA Register your interest today to be the first to hear when registration opens for #PrevConf26. | |
| | | | The British Association for Cancer Research are hosting a conference on the role of the immune system in cancer development and treatment.
From 10–12 September 2025, you can expect to hear the latest in antibody immunotherapy, technological advances for deconvoluting cancer immunology, next generation cellular therapies and translating ideas to the clinic.
Abstract submission deadline: 11 July 2025
Early-bird registration deadline: 1 August 2025. | |
|
---|
|
|
|
|
| Maximise the impact of patient data |
| We can't achieve our research goals without the public trusting that we’re using their health data responsibly to achieve better patient outcomes.
We’re running a webinar on 16 July from 12 pm to help you get patient and public involvement and engagement right in any of your research projects that use their data.
Meet our panel of speakers who will be there to answer your questions: |
| - Matt Howard-Murray, Public Involvement Lead of our Research Data Strategy
- Harriet Unsworth, lead of our public involvement and diversity data community
- Samaira Khan from the Public Engagement in Data Research Initiative at Health Data Research UK
- Jo Gumbs and Chris Carrigan from use MY data
| |
|
|
|
|
|
Funding & research opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | Applications accepted year round |
|
---|
|
| |
|
|
| Together we are beating cancer |
| | |
---|
|
|
|
| You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|